# LINEZOLID

- Oxazolidinone antibacterial agent
- Active against: Gram positive bacteria (including MRSA and VRE), anaerobes including *Bacteroides fragilis*, and *Peptostreptococcus sp*, multidrug resistant TB and *nocardia*.

## WHEN TO CONSIDER TDM

Consider TDM in **all patients** receiving linezolid and if >**14 days** therapy is planned (weekly if stable) given significant haematological adverse effects. Strongly recommended in patients with impaired haematological adverse effects or underlying **dialysis** and for **elderly patients**.

## PHARMACOKINETICS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>100%</td>
</tr>
<tr>
<td>Protein binding</td>
<td>30%</td>
</tr>
<tr>
<td>Clearance</td>
<td>As metabolites: 59% Unchanged in urine: 30%</td>
</tr>
<tr>
<td>Elimination t½</td>
<td>5-7 hours</td>
</tr>
</tbody>
</table>

## SAMPLE COLLECTION TIME

**Trough sample, 48 hours** following initiation or dose change:

## REQUESTING & COLLECTION

Collect 4 mL in a purple top (EDTA) tube (no gel separator).

**Important information required on request form:**

1. Time and date of last dose
2. Time since last dose change/commencement
3. Time of blood sample collection
4. Dosing regimen (dose and frequency)

## HANDLING & TRANSPORT

Sample must be delivered to laboratory within 1 hour of collection. If not delivered to the lab within 2 hours of collection, centrifuge, separate plasma and freeze within 3 hours of collection.

## AVAILABILITY

Test generally performed 5 days a week. Specific days and timing should be confirmed with SydPath.

## REFERENCE INTERVALS

**Suggested Therapeutic Targets:**

- Empiric therapy: Trough 2-7 mg/L
- Directed therapy: Trough 4 x MIC
- Toxic Range: > 7 mg/L

Features of toxicity (see MIMS for more details): nausea, vomiting, peripheral nephropathy, thrombocytopenia.

## CONTACT

Patient Results: (02) 8382 9100


## INSTRUCTIONS FOR REFERRING LABORATORIES

Centrifuge, separate plasma within 3 hours of collection, store and transport plasma frozen.

**Document approved: 18/2/2018**

**References:**

3. Product Information: Zyvox(R) tablets, oral suspension, and solution for injection. Pfizer